Designing PTSD Medicine for Women: Why Methylone Needs Sex Specific Testing

Hystelica Editorial · April 2026

In July 2025 the FDA granted Breakthrough Therapy designation to TSND-201 — a pharmaceutical formulation of methylone — for post-traumatic stress disorder. In March 2026, Otsuka Pharmaceutical agreed to acquire its developer, Transcend Therapeutics, for up to $1.225 billion (1). A molecule that spent two decades as an obscure recreational drug is now one of the most commercially significant compounds in psychiatry.

We are not writing about the deal. We are writing about a gap in how it was tested. Methylone works by triggering a simultaneous surge of serotonin, dopamine, and norepinephrine — three neurotransmitter systems that interact, in well-documented ways, with oestrogen, progesterone, and the cycling biology of the female body. PTSD affects women at roughly twice the rate it affects men. And yet the published evidence on how methylone behaves in female-specific biology is, at this moment, essentially nonexistent. This is not a story about one molecule. It is a story about a pattern.

The molecule

Methylone is the β-keto analogue of MDMA: structurally near-identical, pharmacologically distinct. It acts as a substrate at the dopamine, norepinephrine, and serotonin transporters, reversing them to pump those neurotransmitters into the synapse (2). Compared with MDMA it has roughly threefold lower affinity for the serotonin transporter and a more balanced catecholaminergic profile (3), around 13-fold lower affinity for VMAT2 — which likely makes it far less neurotoxic (4) — and, critically, no activity at the 5-HT2A receptor, so it is non-hallucinogenic (5). It also acts as a “psychoplastogen,” promoting neuronal growth and improved fear-extinction learning — the process disrupted in PTSD (6). On paper, it is a cleaner MDMA.

The serotonin–LH bridge (and why it cuts both ways)

Classic psychedelics – psilocybin, LSD, DMT – are 5-HT2A receptor agonists. The 5-HT2A receptor isn’t just sitting in the cortex producing mystical experiences; it also sits in the hypothalamus, where it directly regulates gonadotropin release.

Fink and colleagues (1999) showed that the oestradiol-induced LHRH surge in rats is blocked by three different 5-HT2A antagonists, but not by an SSRI – the first direct evidence that 5-HT2A activation is required for the pre-ovulatory surge. Serotonin also stimulates kisspeptin neurons in the preoptic area via 5-HT2 receptors (Buo et al., 2023), giving a second point of contact between the serotonin system and the HPG axis. So the bridge is real: 5-HT2A antagonists suppress LH; 5-HT2A agonists – including psychedelics – can drive it.

This is where things get interesting, and complicated, for PCOS. If a woman with PCOS is sitting in a state of already-elevated LH with rapid GnRH pulses, adding an acute 5-HT2A-driven LH surge is the wrong direction. It could, in theory, make ovarian androgen output worse. But the pharmacology is dose- and state-dependent, and the post-acute effect – what happens to the system hours, days, and weeks after dosing – may be the actual therapeutic lever. That post-acute effect seems to run through a different mechanism entirely: the stress axis.

What the Phase 2 trial showed

The Phase 2 IMPACT-1 trial randomised 65 patients with severe PTSD to four weekly oral doses of TSND-201 or placebo. It met its primary endpoint: a placebo-adjusted improvement of −9.64 points on the CAPS-5 at Day 64 (p = 0.011), with significant separation as early as Day 10. Loss of PTSD diagnosis reached 60.7% versus 30.8% on placebo (7). For a field with no new PTSD drug in two decades and only two modestly effective approved medications, these are genuinely important numbers.

But 60% of participants were women, and the trial was never powered to ask whether the drug works the same way in them. There is no published sex-stratified analysis — and with 39 women and 26 men, there could not meaningfully be one. That is acceptable for a proof-of-concept study. It is not acceptable as the foundation for a Phase 3 programme aimed at a predominantly female condition.

Oestrogen, hormones, and the monoamine system

Oestrogen modulates the exact systems methylone acts on. It enhances dopamine release, upregulates dopamine and serotonin receptors, and can substantially amplify the response to drugs acting on those pathways (8). In practical terms, the same dose could land differently in the same woman at different points in her cycle, because the receptor landscape shifts week to week.

The evidence comes straight from methylone’s closest cousin. In rodents, MDMA produces markedly greater effects in females than males — and removing the ovaries abolishes the difference. The researchers’ conclusion was blunt: the heightened female sensitivity reflects “an increased reactivity of the serotonin system due to the effect of ovarian hormones” (8). In humans, women are more sensitive to MDMA’s acute effects and its aftermath: a study of 430 regular users found post-use serotonin depletion hit women’s mood harder (9), and women are nearly twice as likely to seek medical help after taking it. A 2026 study used cell-based, behavioural, and structural techniques in male and female mice to show that MDMA’s effects on serotonin signalling and cortical plasticity are both stereoselective and sex-dependent — one enantiomer produced a behavioural response in female mice and none at all in males (10). Its authors called explicitly for sex to be treated as a biological variable in trials of entactogens. Methylone is an entactogen.

Hormones also shape the whole pharmacokinetic journey — gut transit, and the P450 liver enzymes that metabolise most psychiatric drugs — so women can reach different plasma levels at identical doses (11). A dose that is therapeutic in the follicular phase may be too little, or too much, in the luteal phase. We know this happens with other psychiatric drugs. We have no data on whether it happens with methylone.

None of this is niche. It is the predictable consequence of a research culture that, for decades, excluded women from early-phase trials precisely because hormonal fluctuations were deemed a “confounding variable” — then generalised male data to female patients. The FDA barred that exclusion in 1993, but the foundational pharmacology of drugs like methylone was largely built in male animals and men (12). The very reason women were left out is the exact reason they needed to be in. The logic was always backwards.

Reproductive and hormonal effects

There is no published research on methylone’s effects on the menstrual cycle, ovarian function, reproductive hormones, or fertility — in a drug positioned for millions of women of reproductive age. The concern is mechanistic: the same monoamine systems methylone drives also regulate the hypothalamic-pituitary-gonadal axis that governs reproductive hormones. In long-term methamphetamine users — a harsher drug acting on overlapping pathways — a significant proportion developed abnormal uterine bleeding and hormonal disruption via hypothalamic and pituitary suppression, with normal patterns often not returning for over ten months (13). Methylone is milder and IMPACT-1 involved only four doses — but the axis is sensitive, and the pathways are shared. IMPACT-1 was not designed to detect any of this. Phase 3 must be.

PTSD as a female-predominant condition

None of this sits in a vacuum. The lifetime prevalence of PTSD is roughly 10–12% in women versus 5–6% in men (14). Women are the primary population for this indication — yet the diagnosis was codified largely from male Vietnam veterans, and the criteria and rating scales (including the CAPS-5 used in IMPACT-1) were validated primarily in male combat populations (15). Women’s PTSD — more often rooted in sexual trauma, abuse, and intimate partner violence — was fitted retrospectively into a framework never designed for it. The biology diverges too: women carry greater risk even after controlling for trauma type, cycling oestrogen appears to modulate that vulnerability, and the female neuroendocrine signature of PTSD differs from the male one (14, 16). Women with PTSD also tend to benefit more from therapeutic relationship — a live question for a drug being developed as a once-weekly standalone medication rather than a therapy-assisted one.

Designing Phase 3

Methylone is a genuinely promising molecule. The pharmacology is cleaner than MDMA’s, the efficacy signal is strong, and the designation is warranted. But it is entering large-scale trials for a condition that mostly affects women, without the sex-specific pharmacology to match. We do not know whether oestrogen amplifies its effects the way it amplifies MDMA’s, whether cycle phase alters its metabolism, or what a potent monoamine releaser does to reproductive hormone function.

Phase 3 can close that gap — but only if it is designed to. That means adequate female enrolment with pre-specified, sex-stratified analyses; tracking menstrual cycle phase and hormonal contraceptive use at each dosing visit; and including reproductive-hormone endpoints alongside the psychiatric ones. This is not a burden unique to methylone. It is what rigorous drug development for a female-predominant condition should look like as standard.

Methylone may prove one of the most important psychiatric drugs in a generation. Women deserve to know whether it was developed for them — or simply assumed to work for them.

References

1. Otsuka Pharmaceutical Co., Ltd. & Transcend Therapeutics, Inc. Otsuka Pharmaceutical to Acquire Transcend Therapeutics. Press release. March 27, 2026.
2. Baumann MH, Ayestas MA Jr, Partilla JS, et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology. 2012;37(5):1192–1203. doi:10.1038/npp.2011.304
3. Simmler LD, Buser TA, Donzelli M, et al. Pharmacological characterization of designer cathinones in vitro. British Journal of Pharmacology. 2013;168(2):458–470. doi:10.1111/j.1476-5381.2012.02145.x
4. Warner-Schmidt J, Pittenger C, Stogniew M, Mandell B, Olmstead SJ, Kelmendi B. Methylone, a rapid acting entactogen with robust anxiolytic and antidepressant-like activity. Frontiers in Psychiatry. 2022;13:1041277. doi:10.3389/fpsyt.2022.1041277
5. Luethi D, Kolaczynska KE, Walter M, et al. Pharmacological profile of methylone, butylone, pentylone and brephedrone. Neuropharmacology. 2019;158:107740. doi:10.1016/j.neuropharm.2019.107740
6. Warner-Schmidt J, Stogniew M, Mandell B, et al. Methylone promotes neurite outgrowth and has long-lasting effects on fear extinction learning. Neuropsychopharmacology. 2026;51:631–640. doi:10.1038/s41386-025-02206-z
7. Jones A, Warner-Schmidt J, Kwak H, Stogniew M, Mandell B, Ching THW, Stein MB, Kelmendi B. Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD: A Randomized Clinical Trial. JAMA Psychiatry. 2026;83(5):469–477. doi:10.1001/jamapsychiatry.2025.4625
8. Becker JB, Hu M. Sex differences in drug abuse. Frontiers in Neuroendocrinology. 2008;29(1):36–47. doi:10.1016/j.yfrne.2007.07.003
9. Verheyden SL, Henry JA, Curran HV. Acute, sub-acute and long-term subjective consequences of ‘ecstasy’ (MDMA) consumption in 430 regular users. Human Psychopharmacology. 2003;18(7):507–517. doi:10.1002/hup.529
10. Gaines-Smith MC, Silverman JM, Fiorillo M, et al. Stereoselective, sex-dependent 5-HT2A receptor modulation of cortical plasticity by MDMA in mice. Neuropsychopharmacology. 2026;51(6):1011–1022. doi:10.1038/s41386-025-02313-x
11. Franconi F, Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. British Journal of Pharmacology. 2014;171(3):580–594. doi:10.1111/bph.12362
12. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics. 2009;48(3):143–157. doi:10.2165/00003088-200948030-00001
13. Shen WW, Zhang YS, Li LH, Liu Y, Huang XN, Chen LH, Zhou W. Long-term use of methamphetamine disrupts the menstrual cycles and hypothalamic-pituitary-ovarian axis. Journal of Addiction Medicine. 2014;8(3):183–188. doi:10.1097/ADM.0000000000000021
14. Olff M, Langeland W, Draijer N, Gersons BPR. Gender differences in posttraumatic stress disorder. Psychological Bulletin. 2007;133(2):183–204. doi:10.1037/0033-2909.133.2.183
15. National Center for PTSD, U.S. Department of Veterans Affairs. Research on Women, Trauma and PTSD. Updated 2023. ptsd.va.gov
16. Christiansen DM, Elklit A. Risk factors predict post-traumatic stress disorder differently in men and women. Annals of General Psychiatry. 2008;7:24. doi:10.1186/1744-859X-7-24